Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells

International Journal of Cancer

Volumn 130, Issue 8, 2012, Pages 1755-1767

  Rouette, Alexandre ^a   Parent, Sophie ^a   Girouard, Julie ^a   Leblanc, Valérie ^a   Asselin, Eric ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

Akt; Bcl 2; chemoresistance; cisplatin; PKC

Indexed keywords

CISPLATIN; CYCLOHEXIMIDE; DACTINOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN KINASE B BETA; PROTEIN KINASE C;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEC 1 A; CELL STRAIN ISHIKAWA; CELL STRAIN KLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STABLE EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NAPHTHALENES; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIME FACTORS;

EID: 84857494866     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26183     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Vermorken JB, Hoekman K,. Chemotherapy for gynecologic malignancies. Curr Opin Oncol 1995; 7: 457-65.
3. Kelland L,. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-84.
4. Del BB, Valentini MA, Zunino F, Comporti M, Maellaro E,. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 2001; 20: 4591-5.
5. Gross A, Jockel J, Wei MC, Korsmeyer SJ,. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-85.
6. Oltvai ZN, Milliman CL, Korsmeyer SJ,. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
7. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ,. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705-11.
8. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC,. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-305.
9. Yip KW, Reed JC,. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-406.
10. Nishizuka Y,. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693-8.
11. Reyland ME,. Protein kinase C isoforms: multi-functional regulators of cell life and death. Front Biosci 2009; 14: 2386-99.
12. Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, et al. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol 2009; 64: 803-10.
13. Villar J, Quadri HS, Song I, Tomita Y, Tirado OM, Notario V,. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res 2009; 69: 102-10.
14. Martin V, Garcia-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Sanchez-Sanchez A, Antolin I, Medina M, Rodriguez C,. Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death. Cancer Lett 2010; 287: 216-23.
15. Itano Y, Ito A, Uehara T, Nomura Y,. Regulation of Bcl-2 protein expression in human neuroblastoma SH-SY5Y cells: positive and negative effects of protein kinases C and A, respectively. J Neurochem 1996; 67: 131-7.
16. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA,. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA 1991; 88: 4171-5.
17. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR,. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-41.
18. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR,. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-71.
19. Miwa W, Yasuda J, Murakami Y, Yashima K, Sugano K, Sekine T, Kono A, Egawa S, Yamaguchi K, Hayashizaki Y, Sekiya T,. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun 1996; 225: 968-74.
20. Walker KS, Deak M, Paterson A, Hudson K, Cohen P, Alessi DR,. Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem J 1998; 331: 299-308.
21. Nakatani K, Sakaue H, Thompson DA, Weigel RJ, Roth RA,. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Commun 1999; 257: 906-10.
22. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE,. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275: 10761-6.
23. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z,. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-9.
24. Deng X, Ruvolo P, Carr B, May WS, Jr,. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 2000; 97: 1578-83.
25. Shankar E, Krishnamurthy S, Paranandi R, Basu A,. PKCepsilon induces Bcl-2 by activating CREB. Int J Oncol 2010; 36: 883-8.
26. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E,. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008; 13: 259-71.
27. Yang L, Qiao G, Ying H, Zhang J, Yin F,. TCR-induced Akt serine 473 phosphorylation is regulated by protein kinase C-alpha. Biochem Biophys Res Commun 2010; 400: 16-20.
28. Kane LP, Shapiro VS, Stokoe D, Weiss A,. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999; 9: 601-4.
29. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D,. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51-9.
30. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E,. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004; 94: 785-95.
31. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X,. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
32. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB,. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
33. Crescenzi E, Criniti V, Pianese M, Tecce MF, Palumbo G,. Differential expression of antiapoptotic genes in human endometrial carcinoma: bcl-XL succeeds bcl-2 function in neoplastic cells. Gynecol Oncol 2000; 77: 419-28.
34. Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H,. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 2009; 30: 1517-27.
35. Ioffe OB, Papadimitriou JC, Drachenberg CB,. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998; 29: 1150-9.
36. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME,. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41.
37. Van Themsche C, Lafontaine L, Asselin E,. X-linked inhibitor of apoptosis protein levels and protein kinase C activity regulate the sensitivity of human endometrial carcinoma cells to tumor necrosis factor alpha-induced apoptosis. Endocrinology 2008; 149: 3789-98.
38. Ruvolo PP, Deng X, Carr BK, May WS,. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998; 273: 25436-42.
39. Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR, Bradford AP,. Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol 2008; 39: 21-9.
40. Haughian JM, Jackson TA, Koterwas DM, Bradford AP,. Endometrial cancer cell survival and apoptosis is regulated by protein kinase C alpha and delta. Endocr Relat Cancer 2006; 13: 1251-67.
41. Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, Merajver SD,. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005; 65: 8366-71.
42. Haughian JM, Reno EM, Thorne AM, Bradford AP,. Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer 2009; 125: 2556-64.
43. Siddik ZH,. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.
44. Dent P, Grant S,. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 2001; 7: 775-83.
45. Hollander MC, Fornace AJ, Jr,. Induction of fos RNA by DNA-damaging agents. Cancer Res 1989; 49: 1687-92.
46. Moorehead RA, Singh G,. Influence of the proto-oncogene c-fos on cisplatin sensitivity. Biochem Pharmacol 2000; 59: 337-45.
47. Muscella A, Urso L, Calabriso N, Vetrugno C, Rochira A, Storelli C, Marsigliante S,. Anti-apoptotic effects of protein kinase C-delta and c-fos in cisplatin-treated thyroid cells. Br J Pharmacol 2009; 156: 751-63.
48. Muscella A, Urso L, Calabriso N, Ciccarese A, Migoni D, Fanizzi FP, Di JB, Storelli C, Marsigliante S,. Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment. Biochem Pharmacol 2005; 71: 50-60.
49. Urso L, Muscella A, Calabriso N, Ciccarese A, Fanizzi FP, Migoni D, Di JB, Storelli C, Marsigliante S,. Differential functions of PKC-delta and PKC-zeta in cisplatin response of normal and transformed thyroid cells. Biochem Biophys Res Commun 2005; 337: 297-305.
50. Yamamoto K, Ichijo H, Korsmeyer SJ,. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-78.